Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 530-534

  Rey, David ^a   Krebs, Magali ^a   Partisani, Marialuisa ^a   Hess, Georgette ^a   Cheneau, Christine ^a   Priester, Michèle ^a   Bernard Henry, Claudine ^a   De Mautort, Erik ^a   Lang, Jean Marie ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

K65R mutation; Nucleoside analogue combination; Tenofovir; Virologic response; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SKIN ALLERGY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PILOT PROJECTS; VIRAL LOAD; ZIDOVUDINE;

EID: 33845354046     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000245885.74133.d9     Document Type: Article

References (21)

1. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral naïve HIV-infected adults: a randomised equivalence trial. JAMA. 2001;285:1155-1163.
2. Matheron S, Descamps D, Boué F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/ nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8:163-171.
3. Gulick R, Ribaudo H, Shikuma C, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
4. Palmer S, Margot N, Gilbert H, et al. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001;17:1167-1173.
5. Khanlou H, Yeh V, Guyer B, et al. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS. 2005;19:135-140.
6. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921-1930.
7. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in a once-daily regimen of abacavir, lamivudine, and tenofovir: the TONUS study [abstract 52]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
8. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment-naive, HIV-infected patients receiving a once-daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF [abstract 51]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
9. The AVANTI Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet. 1999;353:2061-2064.
10. Centers for Diseases Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
11. Kaleebu P, on behalf of the DART Trial. 48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial. [abstract WeOaLB0203]. Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro.
12. Mauss S, Milinkovic A, Hoffmann C, et al. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. AIDS. 2005;19:101-103.
13. Perez-Elias MJ, Moreno S, Gutierrez C, et al. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS. 2005;19:695-698.
14. Arribas JR. The rise and the fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. J Antimicrob Chemother. 2004;54:587-592.
15. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22-33.
16. Valer L, Martin-Carbonero L, de Mendoza C, et al. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS. 2004;18:2094-2096.
17. Kuritzkes DR. Less than the sum of its parts: failure of a tenofovirabacavir-lamivudine triple-nucleoside regimen. J Infect Dis. 2005;192:1867-1868.
18. Elion R, Cohen C, DeJesus E, et al. COL40263: resistance and efficacy of once daily Trizivir and tenofovir DF in antiretroviral naive subjects [abstract 53]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
19. Moyle G, Nelson M, Higgs C, et al. A randomized open label comparative study of Combivir + efavirenz (2-class triple therapy) versus Trizivir + tenofovir (single-class quadruple therapy) in initial therapy for HIV infection [abstract H-1131]. Presented at: American Society for Microbiology 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.
20. Pozniak AL, Gallant JE, DeJesus E, et al, for the Study 934 Team. Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients. [abstract WeOa0202]. Presented at: Third IAS Conference on HIV Pathogenesis and Treatment; 2005, Rio de Janeiro.
21. Day SL, Date HAL, Bannister A, et al. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr. 2005;38:301-304.